Loading...
XSHG
603520
Market cap559mUSD
Oct 09, Last price  
8.72CNY
1D
1.99%
1Q
-9.54%
Jan 2017
-50.06%
IPO
24.22%
Name

Zhejiang Starry Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XSHG:603520 chart
P/E
373.76
P/S
1.56
EPS
0.02
Div yield, %
1.75%
Shrs. gr., 5y
5.58%
Rev. gr., 5y
12.33%
Revenues
2.45b
+4.04%
506,582,117574,710,789685,904,773658,482,615695,660,000672,945,253710,939,018890,470,7811,308,841,6341,367,087,2401,999,916,8882,131,239,9872,195,986,1542,350,224,6982,445,155,894
Net income
10m
P
67,567,06535,784,63963,657,74767,704,21168,944,12376,121,54283,116,97793,676,379170,331,968238,729,345323,754,756-75,849,99844,232,091-49,098,97610,228,416
CFO
4m
-98.11%
-41,072,600103,342,43174,993,069144,000,55994,879,3667,679,73418,104,512191,835,586246,768,072174,479,180508,839,385046,126,089193,502,1933,666,738
Dividend
Sep 11, 20260.05 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Founded in 1997 and headquartered in Xianju, China, Zhejiang Starry Pharmaceutical Co.,Ltd. specializes in the research, production, and global distribution of X-CT non-ionic contrast agents and fluoroquinolone pharmaceuticals, along with their key intermediates. The company's extensive range of contrast agent products includes iohexol (and its hydrolysate and iodide derivatives), ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate. For fluoroquinolones, their offerings feature levofloxacin (and its hydrochloride salt), levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate.

Key people

Jinsheng Hu
Chairman of the Board · since 2018
Jian Hu
Vice Chairman of the Board, General Manager · since 2018
Zhihua Jiang
Deputy General Manager
Pengcheng Liu
Deputy General Manager · since 2017
Jinwei Wu
Deputy General Manager, Director
Chuanlong Xu
Deputy General Manager
Fei Yuan
Deputy General Manager
Chaoqun Wu
Secretary of the Board · since 2017
Qinhu Fang
Deputy General Manager, Director
Jinrong Li
Director
Wenhao Hu
Independent Director
Independent Director
IPO date
Mar 09, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT